The effect of communication and disinformation during the COVID-19 pandemic
This study analyses how governments, public health experts and other professionals communicated during the COVID-19 pandemic, and the impact of these communication strategies.
Three years ago … What did the start of the COVID pandemic unleash for you?
As we mark the third anniversary of the declaration of the pandemic, Eloise Todd, co-founder of Pandemic Action Network, writes an opinion on the first 100 days of COVID-19.
EU-US conference on Long COVID
This online conference aimed to shed light on perspectives for addressing long COVID in the EU and the US. It brought together experts from medical, public health, health economics disciplines, patient organisations and policymakers.
WHO’s Science in 5 : Influenza
How does the vaccine combat the Influenza virus? How does WHO track influenza across the world to decide the composition of the vaccine? Dr Sylvie Briand also explains why we are seeing a spike in respiratory diseases in Science in 5
WHO Webinar Series on Trust and Pandemic Preparedness: Trust and pandemics
The first webinar in the series reviews the lessons learned at the intersection of trust and different responses to health emergencies including HIV, Ebola and COVID-19.
Respiratory viruses and infection control
Health Europa spoke to Dr Albert Osterhaus about the burden of respiratory infections.
A Pragmatic Randomized Feasibility Trial of Influenza Vaccines
We conducted a pragmatic, open-label, active-controlled, randomized feasibility trial in Danish citizens aged 65 to 79 years during the 2021–2022 influenza season.
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression
The global surge in the omicron (B.1.1.529) variant has resulted in many individuals with hybrid immunity (immunity developed through a combination of SARS-CoV-2 infection and vaccination).
Persistent SARS-CoV-2 infection in patients seemingly recovered from COVID-19
SARS-CoV-2 infection is clinically heterogeneous, ranging from asymptomatic to deadly.
Two-Years Follow-Up of Symptoms and Return to Work in Complex Post-COVID-19 Patients
Many COVID-19 patients present with severe long-lasting symptoms. They might benefit from a coordination team to manage such complex situations, but late efficacy still needs to be determined.
Pharmacists are encouraged to speak to members of their community about getting both the flu and COVID-19 vaccines at the same time
This 2022-23 flu season in the Northern Hemisphere arrived earlier than expected and we are also seeing a concerning increase in the number of respiratory syncytial virus (RSV) cases.
Stopping epidemics when and where they occur
Governments and the global community must urgently tackle difficult questions about why, how, where, and when diagnostics, treatments, and vaccines are produced, and about who is in control of their availability and distribution.
